Low-density lipoprotein cholesterol-lowering therapy for atherosclerotic cardiovascular disease in the future.
Accumulated evidence from studies has estimated the target for controlling serum low-density lipoprotein (LDL) cholesterol levels in patients at high risk of developing atherosclerotic cardiovascular disease (ASCVD). Although guidelines recommend achieving this target, even with the use of high-intensity statin therapy not all patients reach their target level. Therefore, in the real world, ‘fire-and-forget’ with statins may actually mean forgetting about patients who do not meet their target goals. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - January 22, 2024 Category: Cardiology Authors: Shichiro Abe, Setus Nishino, Tomoaki Kanaya, Masashi Sakuma, Shigeru Toyoda Tags: Editorial Source Type: research
Complete Coronary Revascularization and Outcomes in Patients Undergoing CABG: Insights from the REGROUP Trial
There is growing evidence in support of complete coronary revascularization (CR). Nonetheless there is no universally accepted definition of CR in patients undergoing CABG. We sought to investigate the outcomes of CR defined as surgical revascularization of any territory supplied by a suitable coronary artery with at least 50% stenosis. We performed a pre-planned subanalysis of the REGROUP clinical trial cohort. Of 1,147 patients who underwent CABG, 810 (70.6%) received CR. The primary outcome was a composite of major adverse cardiac events (MACE), including death from any cause, nonfatal myocardial infarction (MI), or rep...
Source: The American Journal of Cardiology - January 22, 2024 Category: Cardiology Authors: Leonid Belyayev, Eileen M. Stock, Brack Hattler, Faisal G. Bakaeen, Scott Kinlay, Jacqueline A. Quin, Miguel Haime, Kousick Biswas, Marco A. Zenati Source Type: research
Impact of Platelet Reactivity on One-year Clinical Outcomes after Endovascular Therapy for Femoropopliteal Lesions
Dual antiplatelet therapy with aspirin plus P2Y12 inhibitor for at least 1 month after endovascular therapy (EVT) is recommended in symptomatic lower extremity arterial disease (LEAD) with femoropopliteal (FP) lesions [1]. However, the pharmacodynamic response to antiplatelet medication differs between individuals. In particular, greater individual differences in platelet reactivity to clopidogrel, one of the P2Y12 inhibitors, have been reported compared to aspirin [2]. Several previous studies evaluated the association of platelet reactivity with clinical outcomes in the area of LEAD management, but their conclusions were...
Source: The American Journal of Cardiology - January 22, 2024 Category: Cardiology Authors: Takuya Tsujimura, Osamu Iida, Mitsuyoshi Takahara, Kazuki Tobita, Daizo Kawasaki, Masahiko Fujihara, Sinya Sasaki, Hiroyoshi Yokoi, Kenji Suzuki, Toshiaki Mano Tags: Brief report Source Type: research
Patients aged 90 years and above with Acute Coronary Syndrome in the Cardiac Intensive Care Unit: Management and Outcomes
The proportion of older patients in cardiac intensive care units (CICUs) is increasing, with acute coronary syndromes (ACS) accounting for a significant proportion of these admissions.(1, 2) Older age has been consistently associated with higher short-term and long-term mortality in CICU patients, especially in those with ACS or cardiogenic shock.(3-6) The small group of CICU patients aged ≥90 years is at particularly high risk of adverse outcomes, both during and after hospitalization.(5) Patients, caregivers, and medical professionals often face uncertainty when deciding on the appropriateness of invasive treatments fo...
Source: The American Journal of Cardiology - January 22, 2024 Category: Cardiology Authors: Dhruv Sarma, Mitchell Padkins, Ryan Smith, Courtney E Bennett, Joseph G. Murphy, Malcolm R. Bell, Abdulla A. Damluji, Nandan S. Anavekar, Gregory W. Barsness, Jacob C. Jentzer Source Type: research
Navigating Heart Failure: Unveiling Sex Disparities in Guideline-Directed Medical Therapy Combinations
Heart failure (HF) remains a prevalent and challenging global health issue, affecting millions of individuals worldwide and posing significant burdens on healthcare systems. Despite considerable advancements in medical science and therapeutic approaches, HF continues to be associated with substantial morbidity, mortality, and healthcare costs. The pursuit of evidence-based first-line guideline-directed medical therapy (GDMT) has played a pivotal role in improving patient outcomes and enhancing the management of HF. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - January 22, 2024 Category: Cardiology Authors: Ahmet Celik, Anil Sahin, Naim Ata, Inci Tugce Colluoglu, Dilek Ural, Emine Arzu Kanik, Mustafa Okan Ayvali, Mustafa Mahir Ulgu, Suayip Birinci, Mehmet Birhan Yilmaz Source Type: research
Peripheral venous pressure accurately reflects invasively measured resting and exercise Fontan pressures
The prognostic implications of elevated Fontan pressures (FP) are well-known. However, in contrast to biventricular circulation, where central venous pressure is easily estimated non-invasively using inferior vena cava collapsibility, echo-Doppler assessment of FP has not been standardized. Moreover, bedside estimation of FP is exceedingly difficult. Accordingly, some have suggested routine cardiac catheterization to avoid delayed recognition of unfavorable hemodynamics. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - January 20, 2024 Category: Cardiology Authors: William R. Miranda, Alexander C. Egbe, Alexander Van De Bruaene, Heidi M. Connolly, Luke J. Burchill, C. Charles Jain Tags: Brief report Source Type: research
1- Versus 3-Month DAPT in Older Patients at a High Bleeding Risk Undergoing PCI: Insights from the XIENCE Short DAPT Global Program
This analysis aimed to evaluate the effect of 1- versus 3-month dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) in older patients. Data from 3 prospective, single-arm studies (XIENCE Short DAPT Program), including patients with high bleeding risk successfully treated with an everolimus-eluting stent (XIENCE, Abbott) were analyzed. DAPT was discontinued at 1 or at 3 months in patients free from ischemic events and adherent to DAPT. Patients were stratified according to age (≥75 and (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - January 19, 2024 Category: Cardiology Authors: Gennaro Sardella, Alessandro Spirito, Samantha Sartori, Dominick J. Angiolillo, Pascal Vranckx, Jose M. De la Torre Hernandez, Mitchell W. Krucoff, Sripal Bangalore, Deepak L. Bhatt, Gianluca Campo, Davide Cao, Bassem M. Chehab, James W. Choi, Yihan Feng, Source Type: research
Cardiovascular Safety of Azithromycin in Patients Hospitalized With COVID-19: A Prespecified Pooled Analysis of the COALITION I and COALITION II Randomized Clinical Trials
The cardiovascular safety from azithromycin in the treatment of several infectious diseases has been challenged. In this prespecified pooled analysis of 2 multicenter randomized clinical trials, we aimed to assess whether the use of azithromycin might lead to corrected QT (QTc) interval prolongation or clinically relevant ventricular arrhythmias. In the COALITION COVID Brazil I trial, 667 patients admitted with moderate COVID-19 were randomly allocated to hydroxychloroquine, hydroxychloroquine plus azithromycin, or standard of care. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - January 18, 2024 Category: Cardiology Authors: Remo H.M. Furtado, Pedro G.M. Barros e Silva, Henrique A.R. Fonseca, Ary Serpa-Neto, Thiago D. Correa, H élio P. Guimarães, Adriano J. Pereira, Guilherme B. Olivato, Fernando G. Zampieri, Thiago Lisboa, Debora L.M. Junqueira, Maura G. Lapa, Frederico Mo Source Type: research
Long-Term Outcomes in Patients With Chronic Total Occlusion
This study aimed to investigate adverse event rates in patients with stable CAD with and without a CTO. In 3,597 patients with stable CAD (>50% coronary luminal stenosis) who underwent cardiac catheterization, all-cause mortality, cardiovascular mortality, and the composite major adverse cardiac event (MACE) rates for cardiovascular death, myocardial infarction, and heart failure hospitalization were evaluated. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - January 18, 2024 Category: Cardiology Authors: Daniel A. Gold, Pratik B. Sandesara, Vardhmaan Jain, Matthew E. Gold, Nishant Vatsa, Shivang R. Desai, Malika Elhage Hassan, Chenyang Yuan, Yi-An Ko, Kiran Ejaz, Zain Alvi, Wissam A. Jaber, William J. Nicholson, Arshed A. Quyyumi Source Type: research
Editorial Board
(Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - January 17, 2024 Category: Cardiology Source Type: research
Contents
(Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - January 17, 2024 Category: Cardiology Source Type: research
Outcomes of Radial Artery Versus Saphenous Vein as A Second Conduit After Coronary Artery Bypass Grafting
This study aims to compare the clinical outcomes of patients who received RA grafts during CABG with those of patients who received SV grafts. A retrospective, single-institution cohort study was performed in 8,774 adults who underwent isolated CABG surgery with multiple grafts between 2010 and 2022. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - January 17, 2024 Category: Cardiology Authors: Eishan Ashwat, James A. Brown, Sarah Yousef, Danial Ahmad, Yisi Wang, Floyd W. Thoma, Derek Serna-Gallegos, Pyongsoo Yoon, David West, Danny Chu, Johannes Bonatti, David Kaczorowski, Ibrahim Sultan Source Type: research
Percutaneous Coronary Revascularization Strategies for Small Vessel Disease: Is an Old Solution Still in Its Prime?
The recent publication by Kiyohara et al1 entitled “Comparison of Clinical Outcomes Among Various Percutaneous Coronary Intervention Strategies for Small Coronary Artery Disease: A Network Meta-Analysis” brings forth an interesting analysis in terms of treatment of coronary artery disease (CAD) in small vessels. This network meta-analysis of pre sent randomized control trials scrutinizes the efficacy of different percutaneous coronary intervention (PCI) in this subtype of vessels and their consequential clinical outcomes. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - January 17, 2024 Category: Cardiology Authors: Sebastian Mrad, Jean-Francois Tanguay Tags: Editorial Source Type: research
Shedding Light on the Puzzle in the Paradox
A man is as old as his arteries (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - January 17, 2024 Category: Cardiology Authors: Christopher L. Hansen Tags: Editorial Source Type: research
Frailty and P2Y12 Inhibitors: Does The Best Approach Need to Be Black or White?
We have read with interest the manuscript by Ko et al1 about frailty and P2Y12 inhibitors. As the authors state, the choice of the most adequate antiplatelet therapy is key, and it is 1 of the most challenging issues in the care of this subgroup of patients. In their series, the 2 major players limiting the use of prasugrel and ticagrelor were anemia and frailty, but despite these factors, the use of clopidogrel was reduced from 78.3% in the period 2010 to 2013 to 42.1% in the interval 2018 to 2020. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - January 17, 2024 Category: Cardiology Authors: I ñigo Lozano, Jose M. Vegas, Juan Rondan Tags: Readers ’ Comments Source Type: research
